LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML

Epigenetic regulators are recurrently mutated and aberrantly expressed in acute myeloid leukemia (AML). Targeted therapies designed to inhibit these chromatin-modifying enzymes, such as the histone demethylase lysine-specific demethylase 1 (LSD1) and the histone methyltransferase DOT1L, have been de...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Cusan, Monica, Cai, Sheng F., Mohammad, Helai P., Krivtsov, Andrei, Chramiec, Alan, Loizou, Evangelia, Witkin, Matthew D., Smitheman, Kimberly N., Tenen, Daniel G., Ye, Min, Will, Britta, Steidl, Ulrich, Kruger, Ryan G., Levine, Ross L., Rienhoff, Hugh Y., Koche, Richard P., Armstrong, Scott A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5897868/
https://ncbi.nlm.nih.gov/pubmed/29453291
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-09-807024
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados